BACKGROUND: Low levels of circulating fetuin-A are associated with increased mortality in dialysis patients. This study aimed to examine a potential causative role for fetuin-A on mortality by investigating whether a functional polymorphism in the alpha2-Heremans-Schmid glycoprotein (AHSG) gene associates with mortality, and by estimating the causative effect of fetuin-A levels on mortality using a Mendelian randomization design. METHODS:One thousand and forty-three incident dialysis patients were genotyped for the Thr256Ser polymorphism (rs4918) and followed up for 5 years; in 549 patients, serum fetuin-A levels were measured. RESULTS: Carriers of a serine allele displayed lower fetuin-A levels (-0.07 g/L per allele, P < 0.001). A small increased mortality risk was observed for the Thr/Ser and Ser/Ser genotype compared with the Thr/Thr genotype (HR 1.03, 95% CI 0.83-1.28 and HR 1.10, 95% CI 0.78-1.55, respectively). Using the AHSG genotype as an instrumental variable, the causative HR of fetuin-A levels on mortality was estimated as 1.01 per 0.1-g/L increase. Inflammation and diabetes partially modified the association of fetuin-A levels with outcome. CONCLUSIONS: The Thr256Ser polymorphism was weakly associated with mortality, and no causative effect of fetuin-A levels on this outcome was observed. Other risk factors, including inflammation and diabetes, might lead to lower fetuin-A levels, and/or modify the effect of low fetuin-A on mortality in end-stage renal disease patients.
RCT Entities:
BACKGROUND: Low levels of circulating fetuin-A are associated with increased mortality in dialysis patients. This study aimed to examine a potential causative role for fetuin-A on mortality by investigating whether a functional polymorphism in the alpha2-Heremans-Schmid glycoprotein (AHSG) gene associates with mortality, and by estimating the causative effect of fetuin-A levels on mortality using a Mendelian randomization design. METHODS: One thousand and forty-three incident dialysis patients were genotyped for the Thr256Ser polymorphism (rs4918) and followed up for 5 years; in 549 patients, serum fetuin-A levels were measured. RESULTS: Carriers of a serine allele displayed lower fetuin-A levels (-0.07 g/L per allele, P < 0.001). A small increased mortality risk was observed for the Thr/Ser and Ser/Ser genotype compared with the Thr/Thr genotype (HR 1.03, 95% CI 0.83-1.28 and HR 1.10, 95% CI 0.78-1.55, respectively). Using the AHSG genotype as an instrumental variable, the causative HR of fetuin-A levels on mortality was estimated as 1.01 per 0.1-g/L increase. Inflammation and diabetes partially modified the association of fetuin-A levels with outcome. CONCLUSIONS: The Thr256Ser polymorphism was weakly associated with mortality, and no causative effect of fetuin-A levels on this outcome was observed. Other risk factors, including inflammation and diabetes, might lead to lower fetuin-A levels, and/or modify the effect of low fetuin-A on mortality in end-stage renal diseasepatients.
Authors: Robert A Koeth; Kamyar Kalantar-Zadeh; Zeneng Wang; Xiaoming Fu; W H Wilson Tang; Stanley L Hazen Journal: J Am Soc Nephrol Date: 2013-02-21 Impact factor: 10.121
Authors: Jennifer Sjaarda; Hertzel C Gerstein; Salim Yusuf; Darin Treleaven; Michael Walsh; Johannes F E Mann; Sibylle Hess; Guillaume Paré Journal: J Am Soc Nephrol Date: 2018-03-06 Impact factor: 10.121
Authors: C Sritara; A Thakkinstian; B Ongphiphadhanakul; L Chailurkit; S Chanprasertyothin; W Ratanachaiwong; P Vathesatogkit; P Sritara Journal: Osteoporos Int Date: 2014-02-26 Impact factor: 4.507
Authors: Majken K Jensen; Richard A Jensen; Kenneth J Mukamal; Xiuqing Guo; Jie Yao; Qi Sun; Marilyn Cornelis; Yongmei Liu; Ming-Huei Chen; Jorge R Kizer; Luc Djoussé; David S Siscovick; Bruce M Psaty; Joseph M Zmuda; Jerome I Rotter; Melissa Garcia; Tamara Harris; Ida Chen; Mark O Goodarzi; Michael A Nalls; Margaux Keller; Alice M Arnold; Anne B Newman; Ron C Hoogeveen; Kathryn M Rexrode; Eric B Rimm; Frank B Hu; Vasan S Ramachandran; Ronit Katz; James S Pankow; Joachim H Ix Journal: Hum Mol Genet Date: 2017-06-01 Impact factor: 5.121
Authors: Majken K Jensen; Traci M Bartz; Luc Djoussé; Jorge R Kizer; Susan J Zieman; Eric B Rimm; David S Siscovick; Bruce M Psaty; Joachim H Ix; Kenneth J Mukamal Journal: Diabetes Care Date: 2013-06-25 Impact factor: 19.112
Authors: György Temesszentandrási; Krisztián Vörös; Bernadett Márkus; Zoltán Böröcz; Edit Kaszás; Zoltán Prohászka; András Falus; Károly Cseh; László Kalabay Journal: Med Sci Monit Date: 2016-08-04
Authors: Qi Sun; Monik C Jiménez; Mary K Townsend; Eric B Rimm; JoAnn E Manson; Christine M Albert; Kathryn M Rexrode Journal: J Am Heart Assoc Date: 2014-06-24 Impact factor: 5.501